CML-0 is a dubious disease in the field of blood tumours, with complex clinical outcomes and often involving multi-system congestion. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory testing and pathological activation.
A platform can help align a team of nationally and internationally authoritative experts to provide accurate diagnosis and treatment programs. Treatment programs for the treatment and management of CML-0 require individualized development, typically including drug treatment, rehabilitation interventions, and regular follow-up management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to the changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of chronic granulocyte leukemia CMML-0. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.